Side Effects of Antipsychotic Medications
Trial ID or NCT#
NCT00363181
Status
NOT RECRUITING
Purpose
Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to weight gain. We hope to learn in this study whether or not olanzapine directly slows down insulin secretion from the pancreas, thereby increasing the risk of developing diabetes.
Official Title
Does Olanzapine Inhibit the Secretory Response to Insulin Resistance?
Eligibility Criteria
Ages Eligible for Study: 30 Years to 66 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Participants 30-66 years of age - Body mass index (BMI) >25 < 35 kg/m2. - Fasting plasma glucose concentration < 126 mg/dL - Stable on one of the following psychiatric medication: Olanzapine (Zyprexa®), Ziprasidone (Geodon®), Aripiprazole (Abilify®), or Risperidone (Risperdal®) - Stable on psychiatric medication for at least 3 months
Exclusion Criteria:
- - Medications that directly affect insulin-mediated glucose disposal - Intense suicidal impulses/intent - Alcohol or substance abuse for 3 months. - Major medical problems, i.e., clinically unstable medical disorder or condition; cardiovascular, hepatic, renal, gastrointestinal, pulmonary, endocrine or other systemic disease that would, in the investigator's clinical judgment interfere with the endocrine measures obtained in this study.
Investigator(s)
Steven Lindley
Contact us to find out if this trial is right for you.
Contact
Lilla Nikolics, Ms
650-493-5000 Ext. 67289
View on ClinicalTrials.gov